Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Posts Study Confirming OD Risk From ENFit LDT Syringes

Executive Summary

The US FDA has posted a study affirming a safety communication the agency issued in October that warned of overdose risk from certain low dose tip syringes.

You may also be interested in...



FDA Warns Of Overdose Risk For ENFit Syringes

The US FDA issued a safety communication to patients and health care providers about the potential for overdose when using ENFit low dose tip syringes, and also told manufacturers to update labeling to account for the risk.

Stryker Fails To Convince FDA To Exempt Patient-Transport Devices

The US agency didn’t buy Stryker’s argument in its April petition that there is no data suggesting patient-transport devices have a history of false and misleading claims.

Bipartisan Bill Seeks To Address US Supply Chain Issues, Prevent Further Crises

Lawmakers have introduced legislation that would establish a national database to help manufacturers expedite the supply chain and avoid further disruptions.

Topics

UsernamePublicRestriction

Register

MT144748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel